Abstract: SA-PO287
Pruritus in Patients With ESKD on Hemodialysis: Initial Results From a Prospective Patient Survey Study
Session Information
- Hemodialysis and Frequent Dialysis: Potpourri
November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 701 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Thompson, Jeffrey, Cerner Enviza, North Kansas City, Missouri, United States
- Kammerer, Jennifer A., Vifor Pharma Ltd., Redwood City, California, United States
- Oliveira, Juliana H., Vifor Pharma Ltd., Redwood City, California, United States
- Ashka, Lauren Leigh, Cerner Enviza, North Kansas City, Missouri, United States
- Johansen, Kirsten L., Hennepin Healthcare Research Institute, Minneapolis, Minnesota, United States
- Yosipovitch, Gil, University of Miami School of Medicine, Miami, Florida, United States
Background
Chronic kidney disease-associated pruritus (CKD-aP) is common in patients on hemodialysis (HD). Real-world assessment of the patient’s perspective of pruritis is needed. A US-based patient survey assessed treatment, and the humanistic and economic burden of CKD-aP.
Methods
Eligible participants were ≥18 years old with healthcare provider (HCP) diagnosed ESKD on 3 times/week HD. They self-reported itch assessed on a modified 28-day recall period using the worst itch numerical rating scale (WI-NRS; 0=no itch to 10=worst itch), from which they were stratified into mild (1–3), moderate (4–6), and severe (7–10) cohorts. Sleep quality was assessed on a 0–10 scale (10=itch completely interfered with sleep in the past 24 hours).
Results
Of 299 completed surveys (2/3 planned population) from December 2021 to May 2022: 50, 126, and 123 were stratified into mild, moderate, and severe itch cohorts, respectively. Overall participants were 53% female, 53% white/non-Hispanic, 43% on Medicare plans, and 70% on in-center HD. Proportions of patients who had discussed chronic itch with an HCP, were diagnosed with CKD-aP, received HCP-recommended treatment, or were currently taking itch treatment increased with itch severity (Figure). Greater itch severity was associated with high/extremely high self-reported itch burden (mild=4.0%, moderate=26.2%, severe=39.8%), and sleep disruption (mild=2.3, moderate=4.6, and severe=6.4). Topical treatment was ubiquitous in all cohorts (100%) while systemic treatment was limited even in moderate to severe itch cohorts (24–40%).
Conclusion
More severe itch scores were associated with a greater likelihood of patient–HCP engagement about itch and related treatment, and poorer sleep quality. A gap in addressing itch is suggested by a lower rate of HCP-recommended treatment (57%) or HCP-diagnosed CKD-aP (56%) vs patients reporting itch to HCPs (69%), and limited use of systemic treatment in moderate to severe itch cohorts.
Funding
- Commercial Support –